ADOCIA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.44 EUR | -1.15% |
|
+2.72% | -18.20% |
| May. 14 | Adocia SA announced that it has received ?2 million in funding | CI |
| Apr. 24 | Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 50M 54.3M | Sales 2025 * | 86M 93.4M | Capitalization | 137M 149M |
|---|---|---|---|---|---|
| Net income 2024 * | 26M 28.24M | Net income 2025 * | 40M 43.44M | EV / Sales 2024 * | 2.3 x |
| Net cash position 2024 * | 22.5M 24.44M | Net cash position 2025 * | 62.3M 67.66M | EV / Sales 2025 * | 0.87 x |
| P/E ratio 2024 * |
2.57
x | P/E ratio 2025 * |
1.71
x | Employees | 78 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.51% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.15% | ||
| 1 week | +2.72% | ||
| Current month | +12.92% | ||
| 1 month | +8.76% | ||
| 3 months | -5.22% | ||
| 6 months | +6.67% | ||
| Current year | -18.20% |
1 week
9.02
9.99
1 month
7.899.99
Current year
7.8912.40
1 year
3.2416.16
3 years
2.7516.16
5 years
2.7522.60
10 years
2.7594.24
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Soula
FOU | Founder | 53 | 05-12-15 |
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director of Finance/CFO | - | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director/Board Member | 67 | 21-05-20 | |
| Director/Board Member | 58 | 13-06-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 9.44 | -1.15% | 54 588 |
| 24-05-17 | 9.55 | -0.52% | 60,050 |
| 24-05-16 | 9.6 | -1.13% | 56,263 |
| 24-05-15 | 9.71 | +5.54% | 162,080 |
| 24-05-14 | 9.2 | +0.11% | 116,074 |
Real-time Euronext Paris, May 20, 2024 at 11:38 am EDT
More quotes
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
2024-06-12
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
9.55
EUR
Average target price
9.7
EUR
Spread / Average Target
+1.57%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.20% | 149M | |
| +9.70% | 115B | |
| +11.73% | 106B | |
| -2.59% | 21.96B | |
| -13.33% | 21.87B | |
| -5.29% | 19.21B | |
| -4.37% | 18.08B | |
| -38.57% | 17.71B | |
| +6.55% | 14.32B | |
| +34.03% | 12.42B |
- Stock Market
- Equities
- ADOC Stock
